Issue 39, 2008
From the journal:

Dalton Transactions

Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs

Olivia R. Allen,a   Richard J. Knoxb  and  Patrick C. McGowan*a  

* Corresponding authors

a Department of Chemistry, University of Leeds, Leeds, UK
E-mail: p.c.mcgowan@leeds.ac.uk

b Morvus Technology Limited, Tŷ Myddfai, Llanarthne, Carmarthen
E-mail: rknox@morvus.com

Abstract

New neutral and ionic functionalised zirconocene dichloride compounds have been isolated and characterised. The ionic zirconocene exhibits excellent cytotoxicity against a range of human tumour cell lines, which represents the first active anticancer zirconocene dichloride compound.

Graphical abstract: Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs

About
Cited by
Related
Download options Please wait...

Article information

DOI
https://doi.org/10.1039/B812244J
Article type
Communication
Submitted
17 Jul 2008
Accepted
07 Aug 2008
First published
18 Aug 2008

Dalton Trans., 2008, 5293-5295

Permissions

Request permissions

Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs

O. R. Allen, R. J. Knox and P. C. McGowan, Dalton Trans., 2008, 5293 DOI: 10.1039/B812244J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements